Patents by Inventor Toshihiro Sakamoto
Toshihiro Sakamoto has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12087342Abstract: An aluminum alloy disc blank for a magnetic disc made of an aluminum alloy containing Fe: 0.005 to 1.800 mass % with the balance being Al and inevitable impurities, wherein a flatness change of the aluminum alloy disc blank for a magnetic disc when the aluminum alloy disc blank for a magnetic disc is held in the atmosphere at 50° C. or lower for 336 hours is 2.0 ?m or less.Type: GrantFiled: June 22, 2023Date of Patent: September 10, 2024Assignees: UACJ CORPORATION, FURUKAWA ELECTRIC CO., LTD.Inventors: Kotaro Kitawaki, Ryo Sakamoto, Wataru Kumagai, Hideyuki Hatakeyama, Ryohei Yamada, Shinpei Todo, Toshihiro Nakamura
-
Patent number: 12065430Abstract: An indazole compound represented by the following Formula (I) or a salt thereof: wherein X, R1, R2, ring A, L1, L2, L3, and R5 are as defined in this specification.Type: GrantFiled: October 25, 2019Date of Patent: August 20, 2024Assignee: TAIHO PHARMACEUTICAL CO., LTD.Inventors: Toshihiro Sakamoto, Hideki Kazuno, Tetsuya Sugimoto, Hitomi Kondo, Tomohiro Yamamoto
-
Publication number: 20240262842Abstract: Compounds of Formula (I) or (Ia) or their pharmaceutically acceptable salts can inhibit the G12C mutant of Kirsten rat sarcoma (KRAS) protein and are expected to have utility as therapeutic agents, for example, for treating cancer. The disclosure also provides pharmaceutical compositions which comprise compounds of Formula (I) or (Ia) or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.Type: ApplicationFiled: April 27, 2022Publication date: August 8, 2024Inventors: Kazuaki SHIBATA, Hiroki Asakura, Kei AKEMOTO, Toshihiro SAKAMOTO, Hitomi KONDO, Tomohiro YAMAMOTO, Risako MIURA, Patrick SCHÖPF, Juan DEL POZO, George Madalin GIAMBUSU, Thomas H. GRAHAM, Yongxin HAN, Elisabeth T. HENNESSY, Anandan PALANI, Michael RYAN, David L. Sloman, Steven HOWARD
-
Publication number: 20240253776Abstract: A vertical tail of a helicopter has a leading edge and a trailing edge concave toward the leading edge. The helicopter includes a main rotor and a tail rotor for generating anti-torque to cancel torque generated by rotation of the main rotor. The trailing edge is concave within a range within which the vertical tail overlaps a circular region, formed as a rotation range of the tail rotor, in a rotation axis direction of the tail rotor.Type: ApplicationFiled: December 28, 2023Publication date: August 1, 2024Inventors: Mizuki NAKAMURA, Shuzou HAKUTA, Hirotoshi TSUKAMOTO, Masafumi SASAKI, Ryusuke SAKAMOTO, Takumi SHINOTSUKA, Mitsunori FUKUDOME, Hiroshi NAGAI, Hiroshi TAGUCHI, Toshihiro YOKOYAMA
-
Publication number: 20240246968Abstract: Compounds or their pharmaceutically acceptable salts can inhibit the G12C mutant of Kirsten rat sarcoma (KRAS) protein and are expected to have utility as therapeutic agents, for example, for treating cancer. The disclosure also provides pharmaceutical compositions which comprise compounds disclosed herein or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.Type: ApplicationFiled: April 27, 2022Publication date: July 25, 2024Inventors: Kazuaki SHIBATA, Hitomi KONDO, Tomohiro YAMAMOTO, Toshihiro SAKAMOTO, Hiroki ASAKURA, Kei AKEMOTO, Risako MIURA, Tetsuya SUGIMOTO, Juan DEL POZO, George Madalin GIAMBUSU, Thomas H. GRAHAM, Yongxin HAN, Elisabeth T. HENNESSY, Shuhei KAWAMURA, Michael RYAN
-
Publication number: 20230049402Abstract: The present invention provides a phenol compound represented by the following Formula (I) or a salt thereof: wherein R1, R2, R5, L1, L2, L3, A, X, and m are as described in the specification.Type: ApplicationFiled: December 6, 2019Publication date: February 16, 2023Inventors: TOSHIHIRO SAKAMOTO, HIDEKI KAZUNO, HITOMI KONDO, TOMOHIRO YAMAMOTO, TETSUYA SUGIMOTO
-
Publication number: 20230023023Abstract: The present invention provides an antitumor agent comprising a compound or a pharmaceutically acceptable salt thereof that covalently binds to GTP-bound KRASG12C as an active ingredient.Type: ApplicationFiled: October 29, 2020Publication date: January 26, 2023Inventors: KAZUAKI SHIBATA, YUICHI KAWAI, HIROKI ASAKURA, TETSUYA SUGIMOTO, NAOKI EGASHIRA, TOMOHIRO YAMAMOTO, TATSUYA SUZUKI, YUKI KATAOKA, TAKESHI SAGARA, TOSHIHIRO SAKAMOTO, HITOMI KONDO, CHRISTOPHER CHARLES FREDERICK HAMLETT, PATRICK SCHÖPF, DAVID GEOFFREY TWIGG
-
Publication number: 20210395234Abstract: An indazole compound represented by the following Formula (I) or a salt thereof: wherein X, R1, R2, ring A, L1, L2, L3, and R5 are as defined in this specification.Type: ApplicationFiled: October 25, 2019Publication date: December 23, 2021Inventors: TOSHIHIRO SAKAMOTO, HIDEKI KAZUNO, TETSUYA SUGIMOTO, HITOMI KONDO, TOMOHIRO YAMAMOTO
-
Patent number: 10538528Abstract: The invention of the present application provides a compound represented by Formula (I) or a salt thereof, which exhibits an inhibitory activity against at least one kinase selected from the group consisting of Akt kinase, Rsk kinase, and S6K kinase and/or a cell proliferation inhibiting effect and is useful as a prophylactic and/or therapeutic agent for diseases associated with the above-mentioned kinases, particularly cancer.Type: GrantFiled: May 19, 2017Date of Patent: January 21, 2020Assignee: Taiho Pahrmaceutical Co., Ltd.Inventors: Tetsuya Sugimoto, Toshihiro Sakamoto, Fuyuki Yamamoto, Yu Kobayakawa, Naoki Egashira, Koji Ichikawa, Takumitsu Machida
-
Publication number: 20190292190Abstract: The invention of the present application provides a compound represented by Formula (I) or a salt thereof, which exhibits an inhibitory activity against at least one kinase selected from the group consisting of Akt kinase, Rsk kinase, and S6K kinase and/or a cell proliferation inhibiting effect and is useful as a prophylactic and/or therapeutic agent for diseases associated with the above-mentioned kinases, particularly cancer.Type: ApplicationFiled: May 19, 2017Publication date: September 26, 2019Applicant: Taiho Pharmaceutical Co., Ltd.Inventors: Tetsuya SUGIMOTO, Toshihiro SAKAMOTO, Fuyuki YAMAMOTO, Yu KOBAYAKAWA, Naoki EGASHIRA, Koji ICHIKAWA, Takumitsu MACHIDA
-
Publication number: 20190170713Abstract: The thin layer chromatography plate includes a substrate and a separation layer. The separation layer is disposed on the substrate and is configured to separate multiple components included in a sample from each other. The separation layer includes a first layer and a second layer. The first layer has a porous structure and extends in a first direction. The second layer has a porous structure and extends in the first direction. The first layer and the second layer are arrayed in a second direction orthogonal to the first direction. A zeta potential of the first layer is different from a zeta potential of the second layer.Type: ApplicationFiled: December 6, 2017Publication date: June 6, 2019Inventors: TOSHIHIRO SAKAMOTO, TOSHINOBU MATSUNO
-
Publication number: 20190170683Abstract: Provided is a thin layer chromatography plate that makes it possible to separate a plurality of components from each other more simply and more quickly. Thin layer chromatography plate includes substrate and separation layer that is disposed on substrate for separating multiple components included in a sample from each other. Separation layer has first layer that has a band shape and extends in first development direction and second layer that extends in second development direction orthogonal to first development direction. Second layer is in contact with first layer. First layer includes a hydrophilic porous body. Second layer includes a hydrophobic porous body.Type: ApplicationFiled: December 13, 2017Publication date: June 6, 2019Inventors: TOSHIHIRO SAKAMOTO, CHIAKI SHIDO
-
Publication number: 20170281392Abstract: The present invention is to provide a shirt for correcting bone alignment that has a capability to correct the alignment of the sternum and the ribs and reduce burden on user's body. The shirt for correcting bone alignment 1 includes a shirt part 10 that is formed from a stretch fabric; a first restraint part 20 that is formed on the right or the left side in the upper-half of the front body of the shirt part 10, the first restraint part 20 being less stretch than the fabric of the shirt part 10; and a second restraint part 30 that is formed on the different side from the first restraint part 20 in the upper-half of the back body of the shirt part 10, the second restraint part being less stretch than the fabric of the shirt part 10.Type: ApplicationFiled: August 9, 2016Publication date: October 5, 2017Inventor: Toshihiro SAKAMOTO
-
Patent number: 9145414Abstract: The present invention provides a compound represented by the following general formula (I) or a salt thereof which has a Syk inhibitory effect (in the formula R1 represents a hydrogen atom or an optionally substituted C1-C6 alkyl group; A represents a hydrogen atom, an optionally substituted C1-C8 alkyl group, an optionally substituted C2-C6 alkenyl group, an optionally substituted C2-C6 alkynyl group, an optionally substituted C3-C10 cycloalkyl group, an optionally substituted C6-C14 aromatic hydrocarbon group, an optionally substituted 4- to 10-membered unsaturated heterocyclic group, or an optionally substituted 4- to 10-membered saturated heterocyclic group, or optionally forms a 4- to 10-membered unsaturated heterocyclic ring or a 4- to 10-membered saturated heterocyclic ring together with R1 and the nitrogen atom bonded thereto; R2 represents a hydrogen atom or an optionally substituted C1-C6 alkyl group; and B represents an optionally substituted unsaturated heterocyclic group).Type: GrantFiled: September 28, 2012Date of Patent: September 29, 2015Assignee: TAIHO PHARMACEUTICAL CO., LTD.Inventors: Toshihiro Sakamoto, Takashi Mita, Kazuaki Shibata, Yoshio Ogino, Hideya Komatani
-
Publication number: 20140343038Abstract: The present invention provides a compound represented by the following general formula (I) or a salt thereof which has a Syk inhibitory effect (in the formula R1 represents a hydrogen atom or an optionally substituted C1-C6 alkyl group; A represents a hydrogen atom, an optionally substituted C1-C8 alkyl group, an optionally substituted C2-C6 alkenyl group, an optionally substituted C2-C6 alkynyl group, an optionally substituted C3-C10 cycloalkyl group, an optionally substituted C6-C14 aromatic hydrocarbon group, an optionally substituted 4- to 10-membered unsaturated heterocyclic group, or an optionally substituted 4- to 10-membered saturated heterocyclic group, or optionally forms a 4- to 10-membered unsaturated heterocyclic ring or a 4- to 10-membered saturated heterocyclic ring together with R1 and the nitrogen atom bonded thereto; R2 represents a hydrogen atom or an optionally substituted C1-C6 alkyl group; and B represents an optionally substituted unsaturated heterocyclic group).Type: ApplicationFiled: September 28, 2012Publication date: November 20, 2014Applicant: TAIHO PHARMACEUTICAL CO., LTD.Inventors: Toshihiro Sakamoto, Takashi Mita, Kazuaki Shibata, Yoshio Ogino, Hideya Komatani
-
Publication number: 20140303178Abstract: The invention relates to compounds of a general formula (I): wherein Ar1 is an optionally-substituted aryl or heteroaromatic group; R1 is an optionally-substituted lower alkyl, lower alkenyl, lower alkynyl or cyclo-lower alkyl group, or is an aryl, aralkyl or heteroaromatic group optionally having a substituent; R2 is a hydrogen atom, a lower alkyl group, a lower alkenyl group or a lower alkynyl group, or is an aryl, aralkyl or heteroaromatic group optionally having a substituent; R3 is a hydrogen atom or a lower alkyl group; R4 is a hydrogen atom, a halogen atom, a hydroxyl group, a lower alkyl group or a group of —N(R1k)R1m; T and U are a nitrogen atom or a methine group, etc. The compounds of the invention have excellent Weel kinase-inhibitory effect and are therefore useful in the field of medicines, especially treatment of various cancers.Type: ApplicationFiled: June 24, 2014Publication date: October 9, 2014Inventors: Takeshi Sagara, Sachie Otsuki, Satoshi Sunami, Toshihiro Sakamoto, Kenji Niiyama, Fuyuki Yamamoto, Takashi Yoshizumi, Hidetomo Furuyama, Yasuhiro Goto, Makoto Bamba, Keiji Takahashi, Hiroshi Hirai, Toshihide Nishibata
-
Patent number: 8791125Abstract: The invention relates to compounds of a general formula (I): wherein Ar1 is an optionally-substituted aryl or heteroaromatic group; R1 is an optionally-substituted lower alkyl, lower alkenyl, lower alkynyl or cyclo-lower alkyl group, or is an aryl, aralkyl or heteroaromatic group optionally having a substituent; R2 is a hydrogen atom, a lower alkyl group, a lower alkenyl group or a lower alkynyl group, or is an aryl, aralkyl or heteroaromatic group optionally having a substituent; R3 is a hydrogen atom or a lower alkyl group; R4 is a hydrogen atom, a halogen atom, a hydroxyl group, a lower alkyl group or a group of —N(R1k)R1m; T and U are a nitrogen atom or a methine group, etc. The compounds of the invention have excellent Weel kinase-inhibitory effect and are therefore useful in the field of medicines, especially treatment of various cancers.Type: GrantFiled: March 22, 2011Date of Patent: July 29, 2014Assignee: MSD K.K.Inventors: Takeshi Sagara, Sachie Otsuki, Satoshi Sunami, Toshihiro Sakamoto, Kenji Niiyama, Fuyuki Yamamoto, Takashi Yoshizumi, Hidetomo Furuyama, Yasuhiro Goto, Makoto Bamba, Keiji Takahashi, Hiroshi Hirai, Toshihide Nishibata
-
Patent number: 8779523Abstract: According to one embodiment, a semiconductor device includes a semiconductor substrate with a p-type conductivity, a buried layer with an n-type conductivity provided on the semiconductor substrate, a back gate layer with a p-type conductivity provided on the buried layer, a drain layer with an n-type conductivity provided on the back gate layer, a source layer with an n-type conductivity provided spaced from the drain layer, a gate electrode provided in a region immediately above a portion of the back gate layer between the drain layer and the source layer, and a drain electrode in contact with a part of an upper surface of the drain layer. A thickness of the drain layer in a region immediately below a contact surface between the drain layer and the drain electrode is half a total thickness of the back gate and drain layers in the region.Type: GrantFiled: June 8, 2012Date of Patent: July 15, 2014Assignee: Kabushiki Kaisha ToshibaInventors: Koji Shirai, Ken Inadumi, Tsuyoshi Hirayu, Toshihiro Sakamoto
-
Patent number: 8614221Abstract: The instant invention provides for substituted fused naphthyridine derivatives that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity by administering the compound to a patient in need of treatment of cancer.Type: GrantFiled: March 10, 2010Date of Patent: December 24, 2013Assignees: Merck Sharp & Dohme Corp., MSD K.K.Inventors: Weiming Fan, Thomas F. N. Haxell, Matthew G. Jenks, Nobuhiko Kawanishi, Shuliang Lee, Hao Liu, Michael J. Malaska, Joseph A. Moore, III, Yoshio Ogino, Yu Onozaki, Bharathi Pandi, Michael R. Peel, Toshihiro Sakamoto, Tony Siu
-
Patent number: 8536193Abstract: The instant invention provides for substituted [1,2,4]triazolo[4,3-a]-1,5-naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms, preferably Akt1. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity, especially Akt1 by administering the compound to a patient in need of treatment of cancer.Type: GrantFiled: May 27, 2009Date of Patent: September 17, 2013Assignees: Merck Sharp & Dohme Corp., MSD K.K.Inventors: Hidetomo Furuyama, Yasuhiro Goto, Nobuhiko Kawanishi, Mark E. Layton, Takashi Mita, Yoshio Ogino, Yu Onozaki, Michael A. Rossi, Toshihiro Sakamoto, Philip E. Sanderson, Jiabing Wang